← Browse by Condition
Medical Condition
atrial fibrillation af
Total Trials
23
Recruiting Now
23
Trial Phases
Phase 2, Phase 2, Phase 3, Phase 4
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 33 million people worldwide and conferring a fivefold increased risk of stroke. Clinical trials in AF address three core problems: rhythm control (restoring and maintaining sinus rhythm), rate control (controlling heart rate in persistent AF), and stroke prevention (anticoagulation). The EAST-AFNET 4 trial established early rhythm control as superior to a rate-control strategy in reducing cardiovascular events, reshaping international guidelines.
Current trials evaluate non-vitamin K oral anticoagulants (NOACs) in underserved populations, pulse field ablation versus radiofrequency ablation (ADVENT trial showed non-inferiority), left atrial appendage occlusion devices (WATCHMAN FLX) versus NOAC therapy in patients with bleeding risk, and novel antiarrhythmic drugs with improved safety profiles. Digital health trials using smartwatch-detected AF episodes are emerging as enrollment and monitoring tools.
CHAβ‚‚DSβ‚‚-VASc score determines anticoagulation eligibility; prior ablation history and type of AF (paroxysmal, persistent, long-standing persistent) determine eligibility for rhythm control trials.
Frequently Asked Questions — atrial fibrillation af Clinical Trials
How many clinical trials are currently recruiting for atrial fibrillation af?
ClinicalMetric currently tracks 23 actively recruiting clinical trials for atrial fibrillation af, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 23. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for atrial fibrillation af?
atrial fibrillation af research spans Phase 2 (3 trials), Phase 3 (2 trials), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a atrial fibrillation af clinical trial?
Eligibility criteria for atrial fibrillation af trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 3
Phase 3 2
Phase 4 2
Top Sponsors
2 trials
2 trials
2 trials
1 trial
1 trial
Recruiting Clinical Trials
NCT07447297
Recruiting
Enrollment
520 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT07278089
Recruiting
Enrollment
3,000 pts
Location
Taiwan
Sponsor
Tze-Fan Chao
NCT06995391
Recruiting
Enrollment
1,000 pts
Location
United States
Sponsor
University of California, San ...
NCT07321964
Recruiting
Enrollment
456 pts
Location
Denmark
Sponsor
Herlev and Gentofte Hospital
NCT06883864
Recruiting
Enrollment
146 pts
Location
China
Sponsor
Beijing Anzhen Hospital
NCT07482020 Phase 2
Recruiting
Enrollment
66 pts
Location
China
Sponsor
Huashan Hospital
NCT07574697
Recruiting
Enrollment
299 pts
Location
United Kingdom
Sponsor
Barts & The London NHS Trust
NCT06618417
Recruiting
Enrollment
936 pts
Location
Denmark
Sponsor
Herlev and Gentofte Hospital
NCT07220525
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
University of California, San ...
NCT07563257
Recruiting
Enrollment
30 pts
Location
Israel
Sponsor
Maxime Zabern
NCT06657404
Recruiting
Enrollment
328 pts
Location
China
Sponsor
Yumei Xue
NCT06960252
Recruiting
Enrollment
80 pts
Location
Taiwan
Sponsor
Ting-Yung Chang
NCT06861673
Recruiting
Enrollment
60 pts
Location
Germany
Sponsor
Asklepios proresearch
NCT07738523 Phase 2, Phase 3
Recruiting
Enrollment
50 pts
Location
Spain
Sponsor
Hospital Universitario Getafe
NCT07434674
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
University of California, San ...
NCT07275697 Phase 4
Recruiting
Enrollment
200 pts
Location
Sweden
Sponsor
Emma Svennberg
NCT07358611
Recruiting
Enrollment
30 pts
Location
Spain
Sponsor
Hospital Clinic of Barcelona
NCT07626411 Phase 3
Recruiting
Enrollment
15,364 pts
Location
United States
Sponsor
Regeneron Pharmaceuticals
NCT07272902
Recruiting
Enrollment
84 pts
Location
Canada
Sponsor
Nova Scotia Health Authority
NCT07436299
Recruiting
Enrollment
400 pts
Location
United States, Belgi...
Sponsor
Oslo University Hospital
NCT07792239 Phase 2
Recruiting
Enrollment
100 pts
Location
Poland
Sponsor
Xyra, LLC
NCT07753200 Phase 4
Recruiting
Enrollment
3,000 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT06646601
Recruiting
Enrollment
157 pts
Location
France
Sponsor
Assistance Publique Hopitaux D...
Related Conditions
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology